What is the recommended dose of ursodeoxycholic acid (UDCA) for adult patients with gallstones?

Ursodeoxycholic Acid Dosing for Gallstone Dissolution

For adult patients with radiolucent gallstones, the recommended dose of ursodeoxycholic acid (UDCA) is 8-10 mg/kg/day, divided into 2-3 doses daily. 1

Dosing Specifics

The FDA-approved dosing for gallstone dissolution is 8-10 mg/kg/day given in 2 or 3 divided doses 1. This recommendation is strongly supported by multiple clinical trials and guideline evidence:

• Optimal efficacy: Studies consistently demonstrate that 8-10 mg/kg/day represents the best balance between efficacy and tolerability 2, 3
• Complete dissolution rates: Approximately 30% of unselected patients with uncalcified gallstones <20 mm achieve complete dissolution within 2 years at this dose 1
• Bedtime dosing advantage: A single bedtime dose of 8.4 mg/kg/day may be more potent than divided mealtime dosing, reducing the cholesterol saturation index more effectively 4

Treatment Duration and Monitoring

• Initial monitoring: Obtain ultrasound at 6-month intervals during the first year 1
• Response assessment: If partial stone dissolution is not evident by 12 months, likelihood of success is greatly reduced and therapy should be discontinued 1, 5
• Treatment duration: Most patients achieving complete dissolution require 1-2 years of therapy 6
• Confirmation: Continue UDCA if stones appear dissolved, then confirm with repeat ultrasound within 1-3 months 1

Patient Selection Factors

Best candidates for UDCA therapy:

• Radiolucent (cholesterol) stones <20 mm in diameter
• Functioning (visualizing) gallbladder on imaging
• Floating or floatable stones (high cholesterol content)
• Small stones (<5 mm have 81% dissolution rate) 1

Poor candidates (rarely achieve dissolution):

• Calcified gallstones
• Stones >20 mm diameter
• Gallbladder nonvisualization developing during treatment 1

Critical Pitfalls to Avoid

1. Do not use higher doses: Doses of 28-30 mg/kg/day should NOT be used, as they may be harmful in late-stage disease 7

2. Do not continue beyond 12 months without response: If partial dissolution is not seen by 12 months, discontinue therapy as success is unlikely 1, 5

3. Monitor for calcification: Acquired surface gallstone calcification develops in approximately 22% of patients at 4 years and predicts treatment failure 5

4. Expect recurrence: Stone recurrence occurs in 30-50% of patients within 2-5 years after complete dissolution 1. Serial ultrasound monitoring is essential after treatment completion.

Special Context: Bariatric Surgery Prevention

For gallstone prevention (not dissolution) in patients undergoing rapid weight loss from bariatric surgery, the dosing differs:

• Sleeve gastrectomy: 500 mg once daily 8
• RYGB or BPD/DS: 300 mg twice daily (600 mg total) 8
• Duration: 6 months post-surgery 9, 10
• Evidence level: Grade A recommendation with strong RCT support 8, 11, 10

This prophylactic regimen reduces gallstone formation from 38% to 8% in post-bariatric patients 10.